Tretman multipla skleroze

Cell Therapy Center EmCell offers multiple sclerosis (MS) treatment using fetal stem cells, with improvements reported in most cases. The goal of MS treatment is to terminate autoimmune aggression, that is, the internal attack against patient’s own nervous system, by disrupting the main mechanism of the disease. This, in turn, leads to the subsiding or even regression of neurological symptoms.

With MS, fetal stem cells have 2 major functions:

• prevention of nerve cell damage: Stem cells are able to help reduce or even prevent damage caused to nerve cells. This process is called “neuroprotection.”
• repair of damaged myelin: In MS, the protective myelin layer surrounding nerve fibers is damaged by the person’s own immune system. Specialized stem cells in the brain can generate myelin-producing cells, which facilitates the repair of myelin. This process is known as “remyelination.”

Within 25 years, Cell Therapy Center EmCell has treated hundreds of patients with different forms of MS and achieved improvements in 83% of cases.

After stem cell treatment, our patients report a number of improvements:

• stabilized condition and the course of the disease alleviated;
• shorter exacerbation period and longer remissions;
• less spasticity in the extremities;
• better gait, coordination and balance;
• improved speech;
• psychoemotional and cognitive improvements;
• boosted immune system;
• improved functioning in the heart, kidneys, liver and bowel;
• better quality of life;
• a chance to return to work if treatment is during the early stages of MS.

Fetal Stem Cells in Multiple Sclerosis. Poster session.

English, jpg, 2.9 Mb

Results of fetal stem cell treatment of multiple sclerosis

Subtypes of multiple sclerosis
Treatment of patients with remitting-relapsing multiple sclerosis
Treatment of patients with secondary progressive multiple sclerosis
Treatment of patients with primary progressive multiple sclerosis
Dynamics of neurological symptoms in 18 multiple sclerosis cases after the stem cell therapy
 

Testimonials

Patient H., 42. Multiple sclerosis

Patient V.A., 28. Multiple sclerosis

Patient H.R., 43. Multiple sclerosis; emphysema; pulmonary insufficiency

Patient L.N., 52. Multiple sclerosis

Patient D.M., 29. Remitting-relapsing multiple sclerosis

Patient R.W., 44. Primary progressive cerebrospinal multiple sclerosis with spastic paraparesis of the lower extremities

Patient M.C., 63. Secondary progressive multiple sclerosis with cerebrospinal involvement, spastic paraparesis of lower extremities and urine retention

Patient A.Z.D., 35. Secondary progressive multiple sclerosis with cerebrospinal involvement and spastic paraparesis of the lower extremities and urine retention

Patient B. B., 36. Secondary progressive multiple sclerosis with cerebrospinal involvement and spastic paraparesis of the lower extremities.  EDSS – 5,0.  Urine incontinence. Moderate type 1 diabetes mellitus

Patient B., 47. Primary progressive (most likely) multiple sclerosis with cerebral involvement and moderate paraparesis of the lower extremities.

Patient R.A., 38. Primary progressive multiple sclerosis with cerebrospinal involvement, spastic paraparesis of lower extremities, urine incontinence. Bedsore on the sacrum.